Pfizer

Tarsus Pharmaceuticals

Jazz Pharmaceuticals

Bristol-Myers

Edgewise Therapeutics

Royalty Pharma

Intra-Cellular Therapies

Eli Lilly

Merck

Johnson & Johnson

SPDR S&P Pharmaceuticals ETF

XPH tracks an equal-weighted index of US pharmaceutical companies.

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Solid Q2 Earnings

The SPDR S&P Pharmaceuticals ETF (XPH) was launched on 06/19/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on 06/19/2006.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Principal Healthcare Innovators Index ETF

Fidelity MSCI Health Care ETF

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

Global X Health Care Covered Call & Growth ETF

SPDR S&P Insurance ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco DWA Healthcare Momentum ETF

Invesco S&P 500 Equal Weight Health Care ETF

SPDR Portfolio S&P 500 Growth ETF

SPDR Portfolio S&P 500 Value ETF

Amplify Weight Loss Drug & Treatment ETF

Vanguard Health Care ETF

SPDR S&P Biotech ETF

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

Health Care Select Sector SPDR Fund

Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?

Finding Opportunity in Unloved Healthcare ETFs

Global X Cloud Computing ETF

iShares S&P Small-Cap 600 Value ETF

Consumer Discretionary Select Sector SPDR Fund

SPDR S&P Transportation ETF

We have highlighted five ETFs from different zones that have plunged the most so far this year but have a solid Zacks ETF Rank.

5 Beaten-Down Top-Ranked ETFs to Buy for a Turnaround

A Look at Pharma ETFs Post Q1 Earnings

The SPDR S&P Pharmaceuticals ETF offers broad-based exposure to the U.S. pharmaceuticals sector, making it a good option for investing in the industry. XPH tracks the performance of the S&P Pharmaceuticals Select Industry Index and provides a cost-effective way to gain exposure to the sector. The top holdings of XPH include Axsome Therapeutics, Eli Lilly, Merck & Co., Pfizer, and Jazz Pharmaceuticals, offering diversification and potential for growth within the pharmaceutical sector.

XPH: A More Balanced Way To Get Exposure To Pharmaceuticals

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Q4 Earnings

Pharma ETFs in Focus Post Q3 Earnings

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Pharma ETFs in Focus Post Q2 Earnings

iShares US Infrastructure ETF

Global X U.S. Infrastructure Development ETF

Value-focused investing comes to rescue if high-growth sectors fail for some reasons.

Cautious on Big Tech & AI? Try These Value-Focused Sector ETFs

XPH's consistent low yield and poor price growth (mostly negative) over both short-run as well as over long-run should be disheartening for investors. Expiration of a large number of patents within 2030, and narrow revenue stream expected from orphan drugs will impact the pharmaceutical industry. Revlimid, Januvia/Janumet, Reyvow, Bedaquiline, Keytruda, Opdivo, Eliquis, Ibrance, Stelara, Trulicity - all drugs are going to become off-patent by 2030.

XPH: Non-Diversified U.S.-Based Large-Cap Pharma ETF Isn't Very Attractive

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.

Pharma ETFs Gain Post Q1 Earnings

XPH gives you exposure to a broad-based cut of the US Pharmaceuticals sector. Patent expirations are a major headwind affecting many companies in the industry.

XPH: Revenue Challenges Ahead For U.S. Pharmaceuticals

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

First Trust NYSE Arca Biotechnology Index Fund

iShares Nasdaq Biotechnology ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares U.S. Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B.

The Fall Of SVB: What It Means For Healthcare Startups

Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.

A Look at Pharma ETFs Post Q4 Earnings

A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies, though none has generated the kind of excitement seen in years past.

Will 2023 be the year that pharma M&A makes a comeback?

Global X Longevity Thematic ETF 

ARK Genomic Revolution Multi-Sector ETF

Virtus LifeSci Biotech Products ETF

BlackRock Future Health ETF

Loncar Cancer Immunotherapy ETF

Global X Telemedicine & Digital Health ETF

Global X Genomics & Biotechnology ETF

 Franklin Genomic Advancements ETF

ROBO Global Healthcare Technology and Innovation ETF

Invesco Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

iShares Global Healthcare ETF

Global X Longevity Thematic ETF

First Trust Indxx Medical Devices ETF

Novo Nordisk

Simplify Health Care ETF

Invesco S&P SmallCap Health Care ETF

ALPS Medical Breakthroughs ETF

Wisdomtree BioRevolution Fund

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Can Health Care Stocks Outperform Again In 2023?

Amgen

Horizon Pharma

Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.

Amgen to Buy Horizon Therapeutics: ETFs to Bet On

XPH invests in U.S. pharmaceuticals stocks. The fund is concentrated in 44 holdings.

XPH: U.S. Pharmaceuticals Stocks Are Probably Fairly Valued, Cyclically Unattractive

The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs for Medicare prescriptions at $2,000 per year, starting in 2025.

What The Inflation Reduction Act Means For Drug Prices

Chemocentryx

Global Blood Therapeutics

Seagen

Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.

Get ready for more merger mania in pharma sector the rest of the year

iShares Evolved U.S. Innovative Healthcare ETF

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

Pharma & Biotech ETFs at One-Month High: Here's Why

Some health care sector ETFs have exposure to companies like Johnson & Johnson, Pfizer, UnitedHealth

Pharma market investments: How ETFs help you dabble in the sector at a modest price

Global X SuperDividend US ETF

DIA and XPH saw massive trading volume in yesterday session.

2 ETFs to Watch for Outsized Volume on Dividend and Pharma

News for SPDR S&P Pharmaceuticals ETF ETF (XPH)